OncoSil Medical files for US FDA approval for specialist device
OncoSil Medical has hit a key milestone in its plans to commercialise its unique OncoSil device for the treatment of dCCA.
Market Cap $18.04B
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
